Evidence map›Paper›PMID 41735586›Full record

Trial reportDiabetologia2026

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.

Hongmei Yan, Jiaojiao Liu, Zhitian Zhang, Shuangshuang Chen, Xinxia Chang, Hang Jin, Xiaoying Li, Yinyin Chen, Ying Chen, Mengsu Zeng

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05367063. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05367063 phase4completed

Canagliflozin Attenuates CMR-Quantified Myocardial Fibrosis in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Ran2022Enrolled45Registered outcomes3Posted comparisons0ConditionsCardiovascular Risk, Type 2 DiabetesArmsCanagliflozin 100mg or Sitagliptin 100mg
PMID 28605608PMID 31434508PMID 16795076PMID 26151266PMID 31167558PMID 31518657PMID 32245746PMID 32578850PMID 33186500other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hongmei Yan *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. yan.hongmei@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0001-7341-4368
Jiaojiao Liu *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhitian Zhang *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Shuangshuang ChenDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinxia ChangDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-5051-6609
Hang JinDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaoying LiDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0006-0308-685X
Yinyin ChenDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. chen.yinyin@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-1192-671X
Ying ChenDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. chen.ying4@zs-hospital.sh.cn.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. zeng.mengsu@zs-hospital.sh.cn.ORCID http://orcid.org/0009-0004-5230-8012

Funding

Joint Research Development Project between Shenkang and United Imaging on Clinical Research and Translation SKLY2022CRT201National Key Research and Development Program of China 2023YFA1802000National Natural Science Foundation of China Youth Fund 82200909Shanghai Pujiang Program 21PJD012the Shanghai Municipal "Explorer Plan" (the second batch) project in 2024 24TS1411000Young and Middle-aged Diabetes Project from Bethune Foundation Z04JKM2022E002
6 · The paper itself

Abstract

aims/hypothesisWe aimed to investigate canagliflozin's effects on myocardial fibrosis, cardiac structure and function, and microcirculation in high-cardiovascular-risk type 2 diabetes mellitus through cardiac magnetic resonance (CMR) quantification, while investigating the cardiovascular protective mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibitors.

methodsThis open-label parallel RCT recruited 45 high-risk participants (18-75 years) with type 2 diabetes (HbA CONCLUSIONS/

interpretationThis study demonstrates that 26 weeks of canagliflozin significantly reduces myocardial fibrosis, as assessed by CMR-derived ECV, in individuals with type 2 diabetes at high cardiovascular risk, providing imaging evidence for SGLT2 inhibitor cardiovascular protection mechanisms.

trial registrationClinicalTrials.gov NCT05367063

fundingThis study was financially supported by the National Key Research and Development programme (2023YFA1802000), the National Natural Science Foundation of China (Youth Fund 82200909), the Young and Middle-aged Diabetes project from the Bethune Foundation (Z04JKM2022E002), the Joint Research Development project between Shenkang and United Imaging on Clinical Research and Translation (SKLY2022CRT201), the Shanghai Municipal 'Explorer plan' (the second batch) project in 2024 (24TS1411000) and the Shanghai pujiang programme (21PJD012).

Indexed as

CanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2MyocardiumSodium-Glucose Transporter 2 InhibitorsAdolescentAdultAgedFemaleFibrosisHumansMagnetic Resonance ImagingMaleMiddle AgedYoung AdultCanagliflozinSodium-Glucose Transporter 2 InhibitorsCanagliflozinCardiac magnetic resonanceCardiovascular riskMyocardial fibrosisSGLT2 inhibitorsType 2 diabetes mellitus

Identifiers

PMID41735586
PMCPMC13109254

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.